Clinical trials: Glioma Tumor Recurrence
Recurrent Glioma, Recurrent Glioblastoma
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma.
- Conditions
- Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor, PTEN Gene Inactivation
- Trial name
- TAC-GReD (NCT04740190)
- Testing
- Talazoparib
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Brain and Central Nervous System Tumors
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00052455
- Testing
- lomustine, procarbazine hydrochloride, temozolomide
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
The study assessed the safety and the dose of the combination of INC280 and buparlisib (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent glioblastoma with PTEN mutations, homozygous…
- Trial name
- NCT01870726
- Testing
- INC280, Buparlisib
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4
A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)
The study aims to investigate the combination of the IDH1R132H peptide vaccine and the dual IDH1/2 inhibitor vorasidenib in patients with recurrent and/or progressive astrocytoma, WHO grade 2,3 and 4.
- Trial name
- iVOCAL (NCT07877415)
- Testing
- IDH1R132H-vac, Vorasidenib 40 mg Oral Tablet, Aldara - Imiquimod 5%
- Volunteers
- 45 people
- Sponsor
- Heidelberg University
Brain and Central Nervous System Tumors
Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, and may be an effective treatment for anaplastic oligodendroglioma. Combining combination chemotherapy with radiation therapy may kill more tumor cells.
- Trial name
- NCT00002840
- Testing
- lomustine, procarbazine hydrochloride, vincristine sulfate
- Where
- 40 sites in Austria, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
CNS Malignancies, Medulloblastoma Recurrent
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come back, gotten worse, or didn't get better with earlier treatments.
- Conditions
- CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma
- Trial name
- JACOB (NCT07017816)
- Testing
- SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Adult Glioblastoma, Magnetic Resonance Imaging
Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma
This study aims to evaluate whether pre-treatment MRI can be used to predict treatment response for anti-angiogenic treatment in glioblastomas.
- Conditions
- Adult Glioblastoma, Magnetic Resonance Imaging, Bevacizimab
- Trial name
- NCT04143425
- Testing
- 3-Tesla conventional magnetic resonance imaging, Advanced imaging without contrast use, Dynamic susceptibility contrast-weighted imaging
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Ho Sung Kim
Adult Medulloblastoma
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma.
- Trial name
- NCT00939484
- Testing
- Pharmacological Study, Vismodegib
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Neurological Cancer
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
- Trial name
- NCT03922555
- Testing
- ASTX727
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma (GBM)
Clinical Study of Oncolytic Virus in Glioblastoma
This clinical trial aims to evaluate whether an oncolytic viral agent can treat recurrent glioblastoma. It will also assess the safety and tolerability of the oncolytic viral agent.
- Trial name
- NCT07145047
- Testing
- oncolytic virus
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mianyang Central Hospital
Brain and Central Nervous System Tumors
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003348
- Testing
- O6-benzylguanine, carmustine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Duke University
Glioblastoma, Glioblastoma Multiforme
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
The purpose of this study is to test the safety and effects of a special type of a cancer vaccine called a 'dendritic cell vaccine' in patients with either newly diagnosed or recurrent glioblastoma.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma
- Trial name
- NCT02010606
- Testing
- Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Cedars-Sinai Medical Center
Glioblastoma, Glioma
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients.
- Trial name
- AVA-CELL (NCT01836536)
- Testing
- Bevacizumab standard of care
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Center Eugene Marquis
Glioblastoma, Gliosarcoma
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Objectives: To determine maximum tolerated dose of CPT-11 when administered following Temodar plus O6-benzylguanine To characterize any toxicity associated w combo of CPT-11 + Temodar plus O6-BG To observe pts for clinical…
- Trial name
- NCT00612638
- Testing
- Temodar, O6-BG, and Irinotecan
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Duke University
Glioblastoma
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
The primary purpose of this study is to test the safety of Pembrolizumab and Temozolomide in treating recurrent glioblastoma and to characterize the effect of this treatment on the participants tumor and immune system..
- Trial name
- NCT05700955
- Testing
- Pembrolizumab and Temozolomide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Glioblastoma Multiforme
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
This open-label, multicenter study will evaluate the safety and efficacy of RO5323441 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma.
- Trial name
- NCT01308684
- Testing
- RO5323441 + bevacizumab [Avastin], bevacizumab [Avastin]
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT00492089
- Testing
- bevacizumab, magnetic resonance imaging, quality-of-life assessment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Glioblastoma Multiforme
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Background: Glioblastoma is the most common and most aggressive type of malignant brain tumor. The drug pazopanib is used to treat people with a type of kidney cancer. Topotecan is used to treat lung cancer.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma, Brain Neoplasms
- Trial name
- NCT01931098
- Testing
- topotecan, pazopanib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma
RATIONALE: New imaging procedures such as magnetic resonance imaging may improve the ability to determine the growth rate of progressive astrocytoma.
- Trial name
- NCT00005084
- Testing
- conventional surgery, magnetic resonance spectroscopic imaging, radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Solid Tumor, Recurrent Glioma
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options.
- Trial name
- NCT04089449
- Testing
- PRT811
- Where
- 11 sites in United States
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.